

### **Amendment to the Specification**

Please amend the last paragraph on page 2 as follows:

Non-covalent inhibitors have been designed from a potent inhibitor of leucine aminopeptidase, Bestatin, according to the characteristics of MetAPs substrates. In modifying it for MetAPs, its chain was replaced with that of norleucine and an alanine was placed at the P1' position. The resulting non-hydrolyzable substrate analog AHPA-Ala-Leu-Val-Phe-Ome (SEQ ID No. 1) inhibited *EcMetAP1* with an  $IC_{50}$  of 5  $\mu$ M, and was the best inhibitor of *EcMetAP1* reported up to now.

The above Amendment is for the purpose of identifying the SEQ. ID No. for the sequence disclosed on page 2, at line 28 of the specification.

**REQUEST**

Applicant is providing herewith an initial CRF copy of the Sequence Listing (for the sequence on page 2, line 28), along with a paper copy of the Sequence Listing and hereby directs the Office to enter the Sequence Listing into the application.

The content of the Sequence Listing information recorded in CRF is identical to that in the written paper copy provided herewith. No new matter has been introduced into the application through the Amendment.

Entry of the Sequence Listing into the application is requested.

Further examination of the present application considering the above Amendment is requested.

Respectfully submitted,

HUDAK, SHUNK & FARINE CO. L.P.A.

A handwritten signature in cursive script, reading "Cheryl L. Farine".

Cheryl L. Farine  
Registration No. 36,796

CLF/js

2020 Front Street, Suite 307  
Cuyahoga Falls, OH 44221  
330-535-2220  
Attorney Docket No.: SKPA-A-PCT-US